667 |
Pre-Intervention Assessment and Optimizing Final Result |
Gary S. Mintz |
Nov. 28. 08 |
666 |
Fundamental and IVUS Measurement |
Myeong-Ki Hong |
Nov. 28. 08 |
665 |
Fundamental and QCA Measurement |
Young-Hak Kim |
Nov. 28. 08 |
664 |
ASPIRE HIGHER: Are There Still Existing Unmet Needs? What We Expect from New Anti-Hypertensive Treatment |
Sang-Hong Baek |
Oct. 24. 08 |
663 |
Explore the Rationale for the Dual Mechanism CCB/ARB Approaches in Hypertension Management |
Jeong Bae Park |
Oct. 24. 08 |
662 |
Improving Outcomes in CV & Metabolic Disease, Landmark Trials Across the Continuum |
Dong-Ju Choi |
Oct. 24. 08 |
661 |
Triple Antiplatelet Therapy After DES Implantation in Patients with High Risk of Restenosis |
Seong-Wook Park |
Oct. 24. 08 |
660 |
Is Triple Anti-Platelet Therapy a Solution for Patients with Aspirin/Plavix Resistance ? |
Jung-Won Suh |
Oct. 24. 08 |
659 |
How Long Patients Will Be on Dual Antiplatelet Therapy? |
Ron Waksman |
Oct. 24. 08 |
658 |
Insights into Antiplatelet Therapy: From CAPRIE to TRITON-TIMI 38 |
Cheol Whan Lee |
Oct. 24. 08 |